Year-end Sale % OFF 
Abstract
Hemoperfusion is an effective modality in removing certain toxins from the blood, especially those that bind to proteins in the body. Hemoperfusion has shown a therapeutic effect on COVID-19 patients. In this case series, we report four patients without effective results following the use of hemoperfusion on the recovery of COVID-19 patients. This study is a case series which carried out on four patients referred to COVID-19 ward of Velayat hospital in Qazvin, Iran. The mean age of the COVID-19 patients was 52.75 ± 18 years. The mean stay at the hospital was 21.5 ± 15.15 days. This study showed that hemoperfusion cannot show a significant therapeutic effect on COVID-19.
Highlights
On March 11, 2020, a pandemic of COVID-19 was announced by the World Health Organization (WHO) as an infectious disease of the century with many detrimental effects on public health [1]
While there is no effective antivirus drug or vaccine for COVID-19, there is a strong need for new treatment measures such as hemoperfusion to improve the prognosis of this group of patients [3]
Hemoperfusion is more effective than other treatments in removing certain toxins from the blood, especially those that bind to proteins in the body or those that are difficult to dissolve
Summary
On March 11, 2020, a pandemic of COVID-19 was announced by the World Health Organization (WHO) as an infectious disease of the century with many detrimental effects on public health [1]. Case Presentation 1 The first patient was a 62-year-old man who has been hospitalized for 15 days and was intubated on the 4th day. The patient did not have comorbidity, while the symptoms of the disease included dry cough, shortness of breath, fever and myalgia. The drugs prescribed for the patient were naproxen, ceftriaxone, diphenhydramine, azithromycin, heparin, hydroxychloroquine, dexamethasone, meropenem, Kaletra, and intravenous immunoglobulin (IVIG). The drugs prescribed for the patient were naproxen, ceftriaxone, diphenhydramine, azithromycin, enoxaparin, atorvastatin, losartan, methylprednisolone, hydroxychloroquine, dexamethasone, meropenem, Kaletra, and IVIG. Case Presentation 4 The fourth patient was a 74-year-old man who has been hospitalized for seven days and was intubated on the 2nd day. The patient received IVIG, and the symptoms of the disease included productive cough, shivering and shortness of breath.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
